Sulodexide and chronic kidney disease: clinical and experimental studies


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Clinical and experimental studies, demonstrating antialbuminuric effects of sulodexide, are discussed.

Full Text

Restricted Access

About the authors

A. A Svistunov

V. V Fomin

References

  1. Nikkila E., Grasbeck R. Heparin in lipoid nephrosis: observations of the effects on edema, proteinuria, serum proteins, lipids and lipoproteins. Acta Med Scand. 1954; 150(1): 39-46.
  2. Poplawski A. Effect of heparin on proteinuria and other biochemical parameters in nephrotic syndrome. Pol Tyg Lek. 1974;29(10):289-291.
  3. Кутырина И.М., Никишова Т.В., Тареева И.Е. Гипотензивное и диуретическое действие гепарина у больных хроническим гломерулонефритом. Тер. арх. 1985; 6: 78-81.
  4. Mandal A.K., Lyden T.W., Saklaen M.G. Heparin lowers blood pressure. Kidney Int. 1995; 47:1017-1022.
  5. Козловская Н.Л. Низкомолекулярные гепарины в практике нефролога. Клин. нефрология. 2011; 1:15-22.
  6. Козловская Н.Л., Шилов Е.М., Шахнова Е.А. и др. Низкомолекулярные гепарины в лечении АФС-нефропатии при первичном и вторичном антифосфолипидном синдроме. Тер. арх. 2004; 9:35-40.
  7. Gambaro G., Baggio B. Glycosaminoglicans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol. Dial. Transplant. 1996; 11: 762-764.
  8. Benck U., Haeckel S., Clorius J.H. et al. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system. Clin J Am Soc Nephrol. 2007; 2(1): 58-67.
  9. Harvey S.J., Miner J.H. Revisiting the glomerular charge barrier in the molecular era. Curr Opin Nephrol Hypertens. 2008; 17: 393-398.
  10. van der Born J., van del Havuel L., Bakker M. et al. Distribution of GBM heparin sulphate proteoglycan core protein and side chanins in human glomerular disease. Kidney Int. 1993;43: 454-463.
  11. Tamsma J., van der Born J., Bruijn J. et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparin sulphate in the glomerular basal membrane. Diabetologia. 1994;37:313-320.
  12. Raats C., Luca M., Bakker M. et al. Reduction in glomerular heparin sulphate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol. 1999; 10:1689-1699.
  13. Pillarisetti S. Lipoprotein modulation of seubendothelial heparin sulphate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000; 10: 60-65.
  14. van der Hoven M.J., Rops A.L., Vladovsky I. et al. Heparanase in glomerular diseases. Kidney Int. 2007;72:543-548.
  15. Lewis E.J., Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy, implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008;31(Suppl. 2): S202-S207.
  16. Wijnhoven T.J., van den Hoven M.J., Ding H. et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008;51:372-382.
  17. Jensen T. Pathogenesis of diabetic vascular disease, evidence for the role of reduced heparin sulphate proteoglycan. Diabetes. 1997; 46 (Suppl. 2): S98-S100.
  18. Wijnhoven T.J., Lensen J.F., Rops A.L. et al. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther. 2007;9:364-377.
  19. Ruggeri A., Guizzardi S., Franchi M. et al. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35:1517-1519.
  20. Karon J., Polubinska A., Antoniewicz A.A. et al. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif. 2007; 25: 510-514.
  21. Ciszewicz M., Polubinska A., Antoniewicz A. t al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009; 153: 118-123.
  22. Kristova V., Liskova S., Sotnikova R. et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57:491-494.
  23. Rossini M., Naito T., Yang H. et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant. 2010; 25(6):1803-1810.
  24. Yung S., Chau M.K., Zhang Q. et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501.
  25. Jin H.Y., Lee K.A., Song S.K. et al. Sulodexide prevents peripheral nerve damage in streptozocin induced diabetic rats. Eur J Pharmacol. 2012; 674(2-3): 217-226.
  26. Li P., Ma L.L., Xie R.J. et al. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. Acta Pharmacol Sin. 2012; 33(5): 644-651.
  27. Solini A., Vergnani L., Ricci F. et al. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5): 819-823.
  28. Sorrenti G., Grimaldi M., Canova N. et al. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997; 25(2): 81-86.
  29. Skrha J., Perusicova J., Pontuch P. et al. Gycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1): 25-31.
  30. Шестакова М.В., Чугунова Л.А., Воронцов А.В. и др. Эффективность сулодексида - низкомолекулярного гепарина - в терапии диабетической нефропатии. Тер. арх. 1997;6:34-37.
  31. Gambaro G., Kinalska I., Oksa A. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002; 13(6): 1615-1625.
  32. Achour A., Kacem M., Dibej K. et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005; 18(5):568-574.
  33. Sulikowska B., Olejniczak H., Muszynska M. et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006; 26(6): 621-628.
  34. Heerspink H.L., Greene T., Lewis J.B. et al.; Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;23(6):1946-1954.
  35. Packham D.K., Wolfe R., Reutens A.T. et al.; Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1): 123-130.
  36. Lewis E.J., Lewis J.B., Greene T. et al.; Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011; 58(5): 729-736.
  37. House A.A., Weir M.A. Sulodexide for diabetic nephropathy: another one bites the dust. Am J Kidney Dis. 2011; 58(5): 692-694.
  38. Blouza S., Dakhli S., Abid H. et al.; DAVET (Diabetic Albuminuria Vessel Tunisia Study Investigators). Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010; 23(4): 415-424.
  39. Masola V., Onisto M., Zaza G. et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transi Med. 2012; 10: 213.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies